Mineralys Therapeutics, Inc. (MLYS)
Largest Insider Buys in Sector
MLYS Stock Price History Chart
MLYS Stock Performance
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Insider Activity of Mineralys Therapeutics, Inc.
Over the last 12 months, insiders at Mineralys Therapeutics, Inc. have bought $7.5M and sold $11.12M worth of Mineralys Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mineralys Therapeutics, Inc. have bought $16.3M and sold $6.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Samsara BioCapital GP, LLC (10 percent owner) — $22.5M.
The last purchase of 555,555 shares for transaction amount of $7.5M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑02‑12.
List of Insider Buy and Sell Transactions, Mineralys Therapeutics, Inc.
| 2024-11-11 | Sale | Chief Medical Officer | 5,026 0.0119% | $15.00 | $75,398 | -15.99% | ||
| 2024-11-06 | Sale | Chief Medical Officer | 25,482 0.0603% | $15.03 | $383,066 | -15.72% | ||
| 2024-10-11 | Sale | Chief Executive Officer | 15,271 0.0325% | $13.52 | $206,433 | -1.70% | ||
| 2024-10-11 | Sale | CFO and Secretary | 10,757 0.023% | $13.57 | $146,004 | -1.70% | ||
| 2024-07-24 | Sale | 550,000 1.1293% | $13.05 | $7.18M | -9.89% | |||
| 2024-07-16 | Sale | Chief Medical Officer | 525 0.0012% | $15.00 | $7,876 | -14.33% | ||
| 2024-07-11 | Sale | Chief Executive Officer | 15,746 0.0331% | $13.34 | $210,075 | -7.81% | ||
| 2024-07-11 | Sale | CFO and Secretary | 10,757 0.0222% | $13.14 | $141,394 | -7.81% | ||
| 2024-06-20 | Sale | Chief Executive Officer | 14,940 0.0276% | $11.73 | $175,237 | +6.49% | ||
| 2024-06-18 | Sale | Chief Executive Officer | 16,607 0.0313% | $11.99 | $199,073 | +5.60% | ||
| 2024-06-17 | Sale | Chief Executive Officer | 17,766 0.0343% | $12.25 | $217,712 | +1.97% | ||
| 2024-06-14 | Sale | Chief Executive Officer | 16,229 0.032% | $12.52 | $203,163 | -1.19% | ||
| 2024-06-13 | Sale | Chief Executive Officer | 39,961 0.0801% | $12.74 | $509,027 | -1.97% | ||
| 2024-06-12 | Sale | Chief Executive Officer | 16,607 0.0334% | $12.77 | $212,013 | -1.19% | ||
| 2024-06-11 | Sale | CFO and Secretary | 96,815 0.1971% | $12.94 | $1.25M | -4.00% | ||
| 2024-05-09 | Sale | Chief Medical Officer | 100 0.0002% | $15.00 | $1,500 | -11.98% | ||
| 2024-02-12 | 10 percent owner | 555,555 1.1801% | $13.50 | $7.5M | -12.98% | |||
| 2023-11-22 | Chief Executive Officer | 4,250 0.004% | $5.97 | $25,356 | +109.06% | |||
| 2023-09-06 | Chief Executive Officer | 2,250 0.0043% | $12.08 | $27,180 | -2.15% | |||
| 2023-08-17 | Chief Executive Officer | 2,250 0.0043% | $12.10 | $27,225 | -1.31% |
Insider Historical Profitability
| Samsara BioCapital GP, LLC | 10 percent owner | 5074916 10.197% | $11.98 | 1 | 0 | |
| Congleton Jon | Chief Executive Officer | 895941 1.8002% | $11.98 | 4 | 8 | +24.98% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 3218106 6.4661% | $11.98 | 1 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | director | 1867229 3.7518% | $11.98 | 1 | 0 |